Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Brexafemme

Chemical Nameibrexafungerp
Dosage FormTablet (oral; 150 mg)
Drug ClassTriterpenoid antifungals
SystemMultiple
CompanySCYNEXIS
Approval Year2021

Indication

  • For the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).
Document TitleYearSource
Brexafemme (ibrexafungerp tablets) Prescribing Information.2022SCYNEXIS Inc., Jersey City, NJ
Document TitleYearSource
Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303).2021Clinical Infectious Diseases
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). 2021BJOG: An International Journal of Obstetrics and Gynaecology
Drug updated on 12/7/2022

More on this drug: Clinical Trials